PharmaShots Weekly Snapshot (April 29-May 03, 2019)


1.AstraZeneca’s Qternmet XR (dapagliflozin, saxagliptin, metformin hydrochloride) Receives FDA’s Approval for Type-2 Diabetes in the US

Published: May 03, 2019 | Tags: AstraZeneca, Qternmet XR, dapagliflozin, saxagliptin, metformin hydrochloride, Receives, FDA, Approval, Type-2 Diabetes, US

2. Celgene Collaborates with Presage to Evaluate Therapies with its CIVO Technology for Multiple Cancers

Published: May 02, 2019 | Tags: Celgene, Collaborates, Presage, Evaluate, Therapies, CIVO Technology, Multiple Cancers

3.Boehringer Ingelheim Signs a Clinical Research Agreement with Amal for the Evaluation of Combination Therapy to Treat Stage IV Colorectal Cancer

Published: May 02, 2019 | Tags: Boehringer Ingelheim, Signs, Clinical Research Agreement, Amal, Evaluation, Combination Therapy, Stage IV, Colorectal Cancer

4. GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma

Published: May 02, 2019 | Tags: GSK, Reports, Results, Trelegy Ellipta, P-III, CAPTAIN Study, Asthma

5. AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies

Published: May 03, 2019 | Tags: AstraZeneca, Signs, Exclusive, Research, License, Option Agreement, Transgene, Co-develop, Oncolytic Immunotherapies, Invir.IO Platform

6. Sanofi’s Dengvaxia Receives FDA’s Approval to Prevent Dengue in Endemic Region in the US

Published: May 01, 2019 | Tags: Sanofi, Dengvaxia, Receives, FDA, Approval, Prevent, Dengue, Endemic Region, US

7.Tmunity Signs an Exclusive Research Agreement with the University of California to Advance TCR Therapies for Pediatric Cancers

Published: May 01, 2019 | Tags:Tmunity, Signs, Exclusive Research Agreement, University of California, Advance, TCR Therapies, Pediatric Cancers

8. Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

Published: April 30, 2019 | Tags: Eisai, Terminates, Worldwide, Development, Commercialization, Agreement, Purdue Pharma, Lemborexant

9. Medtronic’s Attain Stability Quad MRI SureScan Left Heart Lead Receives FDA’s Approval for Heart Failure

Published: April 30, 2019 | Tags: Medtronic, Attain Stability Quad MRI SureScan Left Heart Lead, Receives, FDA, Approval, Heart Failure

10.Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for Advanced Renal Cell Carcinoma

Published: May 01, 2019 | Tags: Exelixis, Initiates, P-III, COSMIC-313, Study, Triple Combination Therapy, Advanced, Renal Cell Carcinoma

11. Medtronic Launches Solitaire X Revascularization Device for Acute Ischemic Stroke in the US

Published: April 30, 2019 | Tags: Medtronic, Launches, Solitaire X Revascularization Device, US, Acute Ischemic Stroke

12. AbbVie’s Skyrizi (risankizumab) Receives European Commission’s Approval for Moderate to Severe Plaque Psoriasis

Published: April 30, 2019 | Tags: AbbVie, Skyrizi, risankizumab, Receives, European Commission, Approval, Moderate, Severe, Plaque Psoriasis

13.Roche Spin-Off Nimble Therapeutics to Commercialize its Drug Development Technology

Published: April 30, 2019 | Tags: Roche, Spins-Off, Nimble Therapeutics, Commercialize, Drug Development Technology

14. AbbVie’s Mavyret (glecaprevir and pibrentasvir) Receives FDA’s Approval for All Genotypes of Hepatitis C in Pediatric Patients

Published: April 30, 2019 | Tags: AbbVie, Mavyret, glecaprevir, pibrentasvir, Receives, FDA, Approval, All Genotypes, Hepatitis C, Pediatric Patients

15. Vertex’s Kalydeco (ivacaftor) Receives FDA’s Approval for Cystic Fibrosis in Eligible Infants Aged 6 to Less than 12 Months

Published: April 30, 2019 | Tags: Vertex, Kalydeco, ivacaftor, Receives, FDA, Approval, Treat, Cystic Fibrosis, Infants

16.Abbott Reports Results of High Sensitive Troponin-I Blood Test for Risk Assessment of Heart Diseases

Published: April 30, 2019 | Tags: Abbott, Reports, Results, High Sensitive Troponin-I Blood Test, Risk Assessment, Heart Diseases

17.AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis

Published: April 30, 2019 | Tags: AstraZeneca, Collaborates, Benevolent AI, Develop, Therapies, Chronic Kidney Disease, Idiopathic Pulmonary Fibrosis

18.Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology

Published: April 29, 2019 | Tags: Janssen, Collaborates, Iktos, Artificial Intelligence, Technology

19. ViiV Healthcare Files NDA for Cabotegravir + Edurant (rilpivirine) to the US FDA to Treat HIV-1 Infection in Adults

Published: April 30, 2019 | Tags: ViiV Healthcare, Files, NDA, Application, FDA, HIV-1, Infection, Adults

20.Sandoz Signs an Agreement with EirGenix to Commercialize Proposed Trastuzumab Biosimilar for HER2+ Cancer Tumors

Published: April 30, 2019 | Tags: Sandoz, Signs, Agreement, EirGenix, Commercialize, Proposed Trastuzumab Biosimilar, HER2+, Cancer Tumors

21.Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP’s Positive Opinion to Treat Hemophilia A in Adolescents and Adults

Published: April 26, 2019 | Tags: Novo Nordisk, Esperoct, turoctocog alfa pegol, N8-GP, Receives, CHMP, Positive Opinion, Treat, Hemophilia A, Adolescents, Adults

22. Acutus Medical’s AcQMap Contact Mapping Software Receives CE Mark Approval

Published: April 26, 2019 | Tags: Acutus Medical, AcQMap Contact Mapping Software, Receives, CE Mark Approval, EU

23. Sanofi and Lexicon’s Zynquista (sotagliflozin) Receive EU’s MAA to Treat Type-1 Diabetes in Adults

Published: April 26, 2019 | Tags: Sanofi, Lexicon, Zynquista, sotagliflozin, Receive, EU, MAA, Treat, Type-1, Diabetes, Adults

24.AstraZeneca and Merck’s Lynparza (olaparib) Receive CHMP’s Positive Opinion for 1L Maintenance Treatment of BRCA-Mutated Advanced Ovarian Cancer

Published: April 29, 2019 | Tags: AstraZeneca, Merck, Lynparza, olaparib, Receive, CHMP, Positive Opinion, 1L, Treatment, BRCA-Mutated, Advanced, Ovarian Cancer